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Abstract: In humans, bilirubin leve ls are influenced by different 
factors. This study aims to evaluate the influence of several nongenetic 
factors (hematologic data, smoking status, alcohol intake, fasting time, 
physical activity, oral contraceptive therapy and caloric intake) and the 
genetic contribution of UGTJ A 1 polymorphisms for the bilirubin lev-
els, in a cohort of young women. Hematologic data, bilirubin and 
screening of TA duplication in the TAT A box region of the UGTJ Al 
gene were performed in 146 young white women. Body mass index 
(BMI) and body fat were determined, and a questionnaire about fasting 
time, smoking habits, oral contraceptive therapy, caloric intake and 
physical activity was performed. Participants were divided into 3 
groups according to the tertiles of bilirubin levels . Subjects from the 
second and third tertile had significant increases in hemoglobin (Hb) 
concentration, hematocrit, mean cell Hb and mean cell Hb concentra-
tion compared with those in the first tertile. Red blood cell count was 
significantly increased in subjects in the third tertile. A significant 
increased frequency was found for the c.-41 _-40dupTA allele in ho-
mozygosity for both second and third tertiles. Multiple linear regression 
analysis showed that the c.-41_-40dupT A allele, Hb, BM! and fasting 
hours were independent variables associated with bilirubin serum 
levels. Hb concentration, fasting time and BMI were identified as 
non genetic causes, together with the genetic UGTJ Al polymorphisms, 
as the main factors associated with variations in bilirubin levels in a 
healthy female population. 
Key Indexing Terms: Bilirubin levels; UGTJAJ; Genetic and nonge-
netic factors; Hemoglobin; Gilbert's syndrome. [Am J Med Sci 2011; 
XXX(XX):l.J 
Bilirubin is the main metabolic end product of heme break-down, and it is a key marker of liver and hematologic 
disorders. Bilirubin itself is a water-insoluble compound that 
requires glucuronidation by a microsomal enzyme, the uridine 
diphosphate glucuronosyltransferase (UGTI A I), to be ex-
creted1 UGTlAl has other endogenous and exogenous sub-
strates, apart from bilirubin, and is implicated in several pro-
cesses, such as estradiol metabolism and detoxification of 
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potential carcinogens and mutagens2 ·3 Changes in UGTlAl 
activity are therefore able to modify water-soluble bilirubin 
glucuronidation, drug metabolism. 
The UGTJAJ gene locus has many variants, and gena-
typing data describe > I 00 single-nucleotide polymorph isms 
within the UGTJAJ gene promoter and coding sequences.2 •3 
Wild-type activity is associated with 6 TA repeats in TATA 
box region of the gene, and the UGTJ A 1 gene expression 
decreases with increasing number of TA repeats. Moderate to 
severe unconjugated hyperbilirubinemia results from a severe 
reduction or from the absence of UGTlAl activity, occurring 
in the Crigler-Najjar syndrome type I and type 11, respectively, 
whereas a mild hyperbilirubinemia occurs in the Gilbert's 
syndrome (GS).4 Homozygosity for the c.-41_-40dupTA allele 
is the most common cause for the Gilbert's syndrome.5 Statis-
tics based on incidence and genotype frequencies provided 
evidence that other inherited and/or acquired factors affect the 
bilirubin metabolism; however, the UGTJAJ gene is known as 
the major factor. 6 
Bilirubin levels present slight daily changes, increasing 
during fasting and in adolescence. A slight increase in bilirubin 
concentration has been reported also during physical exercise, 
stress or menstruation.7 The activity of UGT!Al can also be 
enhanced with alcohol intake and by some drugs,s- 12 or it can 
be down-regulated during infection and inflammation. 12- 14 
Bilirubin in high concentrations is a dangerous me-
tabolite for human health , namely, in newborns that are 
susceptible to toxicity from unconjugated bilirubin, leading 
to Kernicterus if it is not immediately treated. 15 Recent 
evidences suggest that mild bilirubin level s are strong phys-
iologic antioxidants that may give protection against athero-
sclerosis, coronary heart disease and inflammation, all 
known as oxidative stress conditions.16, 17 
In addition to the referred genetic background that reg-
ulates serum bilirubin levels, there are other genetic and non-
genetic factors that may contribute for bilirubin concentration. 
Because hemoglobin (Hb) degradation is the main source of 
bilirubin, it is possible that individual differences in bilirubin 
concentrations could be due, mainly, to differences in Hb 
concentration. Indeed, it was, recently, described that an in-
crease in red cell mass, probably, plays a crucial role in 
hyperbilirubinemia levels, because they would increase to un-
expected higher values in case of GS, 18 eventually triggering 
the clinical manifestation of the disease or its worsening. 
The aim of this study was to evaluate the influence ofHb 
concentration and of several non genetic factors, such as smok-
ing status, alcohol intake, physical activity, oral contraceptive 
therapy, fasting time and caloric intake, and the genetic con-
tribution of UGTJAJ polymorphisms for the bilirubin levels, by 
performing a cohort study in young Portuguese women. 
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MATERIALS AND METHODS
Subjects
We studied a group of 146 randomly selected young
white female students (20.7  2.6 years old) from the north of
Portugal. All participants gave their informed consent to par-
ticipate in this study, and those with liver and/or hematologic
disorders, chronic or acute infection, under medication, other
than contraceptives and with a history of malignancy were
excluded from the study.
All participants were asked to respond to a question-
naire, including questions about fasting time, smoking habits
and oral contraceptive therapy. To assess physical activity, we
applied the Short Form of the International Physical Activity
Questionnaire.19 Body weight and height were determined by
standard anthropometric techniques. Body mass index (BMI)
was calculated according to World Health Organization recom-
mendations. Body fat measurement was performed by a bioel-
ectrical impedance system (Model BC532; TANITA, Tokyo).
Samples and Measurements
Blood samples were collected (ethylenediaminetetraacetic
acid as anticoagulant) to obtain whole blood, plasma and buffy
coat for DNA extraction. Plasma samples were aliquoted and
stored at 70°C, until assayed.
Red blood cell count, total and differential white
blood cell count, Hb concentration, hematocrit (Ht) and
hematologic indices [mean cell volume, mean cell Hb
(MCH), mean cell Hb concentration (MCHC) and red cell
distribution width] were measured by using an automatic
blood cell counter (ABX Micros 60-OT; Horiva-ABX,
France). Plasmtic total bilirubin concentration was deter-
mined using a colorimetric method (diazotized sulfanilic
acid reaction; Roche Diagnostics Co., IN).
Genotype Determination
All participants were screened for the presence of the TA
duplication in the TATA box region of the UGT1A1 gene. This
TATA box region was analyzed by polymerase chain reaction
(PCR) amplification, using the primers previously described by
Bancroft et al,20 with the introduction of a fluorochrome label
in the reverse primer, for subsequent analysis by automated
capillary electrophoresis. In brief, genomic DNA was extracted
from blood samples by using the standard salting out method.
The TATA box region of UGT1A1 gene was analyzed by PCR
amplification. For the reaction mixture, we used the PCR
Master Mix (Promega, Madison, WI). To 25 L of this mixture
(with dNTPs, DNA Taq polymerase and MgCl2) was added 1
L of each primer (10 pmol/L), 1 L of genomic DNA (100
ng/L) and water, for a final volume of 50 L. The protocol of
cycling was performed on a DNA thermocycler GeneAmp PCR
System 9700 (Applied Biosystems, Foster City, CA). The first
step of denaturation at 95°C for 10 minutes was followed by 35
cycles of denaturation at 95°C for 1 minute, annealing at 58°C
for 45 seconds and extension at 72°C for 1 minute; and a final
extension at 72°C for 10 minutes was performed. After PCR, 1
L of the products was separated by automated capillary
electrophoresis (ABI Prism 3130xl Genetic Analyser; Applied
Biosystems) and analyzed by GeneScan software v3.7 along
with the molecular weight marker GeneScan ROX–500 Size
Standard (Applied Biosystems).
Statistical Analysis
For statistical analysis, we used the Statistical Package
for Social Sciences (version 17.0; SPSS, Chicago, IL). Kolm-
ogorov-Smirnov statistics were applied to evaluate sample
normality distribution. Continuous variables without normal
distribution were log transformed. The participants were di-
vided by tertiles of total bilirubin, and multiple comparisons
between the obtained groups were performed by 1-way analysis
of variance, supplemented with Tukey’s HSD post hoc test. For
categorical variables, we used 2 test or Fisher’s exact test to
compare groups. Pearson correlation coefficient was applied to
evaluate relationships between sets of data. Multiple-regression
analysis (stepwise method) was used to find independent vari-
ables associated with total bilirubin levels. The genotype of the
TATA box polymorphism was coded using 2 dummy variables,
one to compare the homozygous for the wild-type allele (ref-
erence category) with heterozygous for the c.-41_-40dupTA,
and the other to compare the wild-type allele with homozygous
for c.-41_-40dupTA. A P value of 0.05 was considered
statistically significant.
RESULTS
To analyze the contribution of Hb and other factors to
the bilirubin blood levels, we divided our population of young
female participants into 3 groups, according to the tertiles of
total bilirubin concentration, the first group 6 mol/L, the
second group between 6 and 9 mol/L and the third group 9
mol/L.
No differences were observed between the 3 groups
when comparing the age of the participants (Table 1). The
hematologic studies showed that subjects from the second and
third tertile had significantly higher Hb concentration, Ht,
MCH and MCHC and lower platelet counts compared with
those in the first tertile (Table 1). The subjects from the third
tertile maintained the same significant changes, and a signifi-
cant increase in red blood cell count, compared with the first
tertile values. No changes were observed between the second
and the third tertile despite the increasing bilirubin concentra-
tion. No significant differences were found between groups for
total and differential white blood cell counts (Table 1).
The frequency for the c.-41_-40dupTA allele in homozy-
gosity increased from the first to the third tertile because a
significant increase was observed between the first and the
second tertile, and the frequency for the latter was significantly
lower than that observed for the third tertile (Table 1). Allele
frequencies of 0.31 for c.-41_-40dupTA allele and of 0.69 for
normal allele were obtained in all population, which are in
Hardy-Weinberg equilibrium (2 test; P  0.029). Moreover,
when compared, total bilirubin concentration, according to
UGT1A1 genotype, a significant and progressive increase
was observed, from the []  [] to the homozygous
c.-41_-40dupTA allele (Figure 1).
No significant differences were observed between the 3
tertile groups of bilirubin concentration, when considering
physical activity, smoking habits, oral contraceptive therapy,
body fat, alcohol ingestion and fasting time. However, a sig-
nificant decrease in BMI was observed in the third tertile
compared with the first tertile (P  0.009; Table 2).
Significant positive correlations were found between
total bilirubin concentration and Hb (r  0.336; P  0.0001),
Ht (r  0.244; P  0.003), MCH (r  0,276; P  0.001) and
MCHC (r  0.326; P  0.0001).
Multiple linear regression analyses showed that the
TATA box gene polymorphism, Hb, BMI and fasting time
account for approximately 44% of the variation in serum total
bilirubin levels (adjusted R2  0.439; P  0.0001). The model
identified the c.-41_-40dupTA allele as the main contributor for
total bilirubin variation (  0.481, P  0.0001 when in
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homozygosity;  0.381, P 0.0001 when in heterozygosity),
followed by Hb (  0.297, P  0.0001), fasting hours ( 
0.292, P  0.0001) and BMI (  0.235, P  0.004).
DISCUSSION
Several studies aimed to clarify the influence of genetic
and nongenetic factors in bilirubin levels.2,3,21–27 Most of them
focused only on genetic or nongenetic factors and included
individuals of both sex and with a wide range of ages. In this
work, we analyzed a cohort of young women with narrow age
range to eliminate the potential interference of age and sex.
Our results showed that TA duplication in the promoter
region of UGT1A1 gene, Hb concentration, fasting time and
BMI are the main determinants of bilirubin levels.
According to bilirubin tertiles, our population showed an
increase in bilirubin concentration that follows the genetic
polymorphism present at the promoter region of the UGT1A1
gene. In fact, we found a higher prevalence of c.-41_-40dupTA
allele in subjects with the highest bilirubin concentrations.
Moreover, when the population was stratified by UGT1A1
genotype, we found significant differences for bilirubin levels
between the 3 different genotypes (Figure 1), showing a strong
association between higher bilirubin levels and the presence of
TA duplication in the promoter region of UGT1A1 gene. This
finding is in accordance with published data that defined the
c.-41_-40dupTA allele as the most important cause of hyper-
bilirubinemia in white population.6,27
Because most of plasma bilirubin results from the catab-
olism of Hb in the macrophages from the reticuloendothelial
system, it is expected that bilirubin concentration will increase
as Hb concentration increases. Our results showed that Hb,
MCH and MCHC were increased in women with bilirubin
levels 6 mol/L (second and third tertile). Moreover, we
found positive and significant correlations between bilirubin
levels and Hb, Ht, MCH and MCHC. These results strongly
suggest that red cell mass and Hb concentration are associated
TABLE 1. Hematologic data, bilirubin levels and UGT1A1 genotype distribution by tertiles of total bilirubin in all population
Participants
(n  146)
Tertiles of total bilirubin levels (mol/L)
T1 (<6.0, n  49) T2 (6.0–9.2, n  49) T3 (>9.2, n  48) Pa
Age (yr) 20.5 (2.3) 20.9 (2.8) 20.3 (2.1) 20.4 (2.0) 0.332
Blood count
RBC (1012/L) 4.6 (0.3) 4.5 (0.2) 4.6 (0.3) 4.7 (0.3)b 0.149
Hemoglobin (g/dL) 13.6 (1.1) 13.0 (1.1) 13.8 (1.0)b 13.9 (1.0)b <0.0001
Hematocrit (%) 40.7 (2.4) 39.8 (2.5) 41.1 (2.2)b 41.3 (2.4)b 0.005
MCV (fL) 88.4 (3.9) 87.6 (4.1) 88.8 (4.1) 88.8 (3.5) 0.231
MCH (pg) 29.4 (1.7) 28.7 (1.8) 29.8 (1.7)b 29.9 (1.4)b 0.001
MCHC (g/L) 33.3 (1.1) 32.8 (1.0) 33.5 (1.1)b 33.7 (1.1)b <0.0001
RDW-CV (%) 12.9 (0.9) 13.1 (0.9) 12.8 (0.8) 12.7 (0.9) 0.341
WBC (109/L) 6.4 (1.3) 6.5 (1.3) 6.6 (1.3) 6.3 (1.6) 0.390
Neutrophil (109/L) 3.4 (1.4) 3.5 (1.4) 3.4 (1.5) 3.2 (1.4) 0.493
Eosinophil (109/L) 0.13 (0.5) 0.12 (0.5) 0.15 (0.5) 0.12 (0.5) 0.377
Basophil (109/L) 0.03 (0.06) 0.02 (0.06) 0.03 (0.05) 0.02 (0.06) 0.075
Monocyte (109/L) 0.4 (0.2) 0.4 (0.1) 0.5 (0.3) 0.4 (0.1) 0.085
Lymphocyte (109/L) 2.4 (0.7) 2.3 (0.6) 2.5 (0.7) 2.3 (0.8) 0.606
Platelets (109/L) 248 (56.9) 267.9 (62.7) 242.9 (54.4)b 234.4 (48.4)b 0.019
TA duplication in UGT1A1 gene
	  	 %, (n)	 48.8 (71) 67.3 (33) 53.1 (26)b 25.0 (12)b,c
	  c.-41_-40dupTA	 %, (n)	 40.8 (59) 33.3 (16) 43.1 (21)b 45.8 (22)b <0.0001
c.-41_-40dupTA %, (n)	 10.9 (16) 0.0 (0) 3.9 (2)b 29.2 (14)b,c
Data are presented as mean (standard deviation) for continuous variables and as percentage (number) for categorical variables.
a P value for 1-way analysis of variance or 2 tests.
b P  0.05 vs. T1.
c P  0.05 vs. T2.
RBC, red blood cells; WBC, white blood cells; MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin
concentration; RDW-CV, coefficient of variation of the red cell width.
FIGURE 1. Total bilirubin plasma levels according to UGT1A1
genotype.
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with interindividual variations in bilirubin levels. This finding
was previously reported in a study with patients with GS18; our
study reports for the first time, in a young female population, an
increase in Hb concentration that follows bilirubin levels (bil-
irubin 6 mol/L). We also found lower platelet counts in
subjects with bilirubin levels higher than 6 mol/L. Low Hb
concentration has been associated with an increased risk for
cardiovascular disease events and mortality in patients with
end-stage renal disease,28 and to heart failure29 in the general
population.31 We doubt whether lower levels of bilirubin
that probably occur in these cases represent an additional
risk, because bilirubin may have an important role in the
prevention of cardiovascular diseases,31,32 as a result of its
antioxidant effect.31
We also found that fasting time is an independent vari-
able associated with total bilirubin concentration. This associ-
ation has been previously reported in subjects who were not
stratified according to UGT1A1 genotype.24,25 The increase of
bilirubin levels with fasting time seems to result from a de-
crease of the intestinal motility and elimination of bile pig-
ments, causing bilirubin accumulation in the intestine—leading
to an increased reflux of bilirubin into the plasma.33 In fasting
subjects with a normal capacity of bilirubin conjugation, the
accumulation of bilirubin in the intestine can be higher com-
pared with those with a low capacity of bilirubin conjugation
because of UGT1A1 polymorphisms, explaining the higher
bilirubin levels found in women with normal number of TA
repeats and with UGT1A1 polymorphisms, with the same
fasting time.
Multivariate regression analysis also showed BMI as an
independent variable associated with total bilirubin concentra-
tion. No significant differences were established for body fat
between the 3 tertiles of total bilirubin levels; however, a trend
for lower values was observed from the lowest to the highest
bilirubin tertile. An inverse correlation between body fat and
BMI with bilirubin concentration has been reported,34,35 but
this association is still poorly clarified.
Regarding the influence of lifestyle variables, data from
literature are still controversial.21,22,26 We also analyzed the
effect of other nongenetic factors in bilirubin levels, such as
physical activity, tobacco smoking, alcohol intake and oral
contraceptive therapy. We did not find any association between
these factors and the changes in bilirubin concentration. This
can be due to the characteristics of our sample, which, for
instance, included only young women who did not have strong
habits of smoking or did exceed the recommended limit of
alcohol ingestion (data not shown).
In conclusion, we studied the effect of several factors
that could contribute for total bilirubin concentration. We found
that Hb concentration, fasting time and BMI are independent
variables significantly associated with total bilirubin concen-
tration in a female population. In the same way, total bilirubin
concentration was strongly affected by the polymorphism pre-
sented in the promoter region of the UGT1A1 gene. Further
studies must be performed to determine the effect of these
factors in different ages, in both men and women, and deter-
mine whether UGT1A1 variations, other than the TA duplica-
tion in the promoter region, could affect the total bilirubin
levels.
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